Wednesday, March 15, 2017
On the Prospects of Cancer Immunotherapy
On the Prospects of Cancer Immunotherapy: Essentially, this therapy boils down to the use of a person's immune system to treat cancer. There are both active and passive forms of immunotherapy. Active immunotherapies mostly involve the extraction of immune cells from a patient's blood (or tumor) to be genetically modified, incubated, and returned to the patient with the intention of targeting a specific cancer. Unfortunately, many active immunotherapies are still in varying phases of development at a number biopharmaceutical companies around the world. In fact, one of the only FDA-approved active immunotherapies is a drug called Provenge, which targets prostate cancer. Regarding passive immunotherapies, however, the use of monoclonal antibodies (or MABs) are the main focus. And they are largely designed to supplement the body's response to the active immunotherapies.